Aim: Demonstrate that preoperative tumor markers are prognostic factor in colon rectal cancer and their high levels are correlated with bad prognosis.
Introduction
Colorectal cancer (CRC) accounts for 13% of all cancers, it represents the third most common neoplasia and it stands for the second leading cause of cancer death in the 27 countries of the European Union [1, 2] . Prognosis of CRC patients is mainly dependent on several factors: pathological, clinical and biological. Although pathologic stage is useful and essential for predicting prognosis in CRC patients, it is difficult to determine in an accurate way the stage prior to the surgical treatment. It is also well known that patients with the same pathological stage show survival heterogeneity. Thus, it is necessary to identify promising prognostic factors that could preoperatively identify patients at high risk of recurrences after surgery or with a bad survival prognosis. Carcinoembrionic Antigen (CEA) and Carbohydrate 19.9 (CA 19.9) are the most common used tumor-associated antigens used in the pre-and post-operative management of patients affected by colon cancer. They can be inexpensively and easily measured increasing their applicability in all patients who will undergo colorectal surgery. There are several reports in the literature demonstrating their useful correlation to post-surgical [3] [4] [5] recurrence but there are few and controversial studies that evaluate their pre-operative prognostic values in both overall and disease-free survival. Our aim is to analyze the survival significance of preoperative serum CEA and CA 19.9 values in patients undergoing potential macroscopic curative surgical procedure for CRC.
Patients and Methods

Patients
We retrospectively analyzed data on two hundred and thirty-one patients with colorectal cancer who underwent macroscopically curative surgery between January 2012 and August 2016.
Statistical analyses
Statistical analyses were conducted using PRISM software and Med Calc Software. Differences between groups were tested with a Chi-square test or T student. Survival rates were calculated using the Kaplan-Meier method, and prognostic factors and survival curves were compared using the log-rank test. Variables, with a statistical P-value less than 0.05 in the univariate analysis, were entered into a multivariate Cox regression analysis. A P-value<0.05 was deemed to be statistically significant. Roc curves were also performed with the statistical software.
Results
Tumor location was 94 times on ascending colon (42%), 13 on transverse colon (5.8%), 77 on descending colon (34.4%) and 40 on rectum (17.8%). All tumors were histologically diagnosed as adenocarcinoma of the colon-rectum and staged according to the TNM staging system. Among the 224 investigated patients, there were 12 patients (5.3%) who were double positive for CEA and CA19-9, 58 patients (25.9%) who were positive for CEA only, and 23 patients (10.3%) who were positive for CA 19-9 only. Preoperative serum CEA level was significantly associated only with T stage and serum albumin level; whereas there were not statistically significant differences between preoperative serum CA19.9 and patients' clinical pathologic characteristics as shown in Tables 1 and 2. Overall Survival (OS) was defined as the time either from surgery or from the last follow-up to death. All the studied patients were dichotomized at the normal value of CEA and Ca 19.9.
Blood sample analyses
Venous blood sampling was taken before surgery and collected in ethylene diamine tetra acetic acid (EDTA) containing tube. CEA and Ca 19.9 were detected by ELISA technique. 
Variables
Low Table 2 : Correlation between preoperative serum CA19.9 Level and clinicopathologic variables; Ca 19.9 cutoff value used is 35 Ui/ml (N/L: Neutrophils to Lymphocytes ratio; N/P: neutrophils to platelets ratio).
Roc curves analysis
CEA sensitivity and specificity for 2 years OS were respectively 62.5% and 85.7% as shown in Figure 1 ; whereas Figure 2 showed CEA sensitivity and specificity for 1-year DFS, which is respectively 50 and 93%. Ca19.9 Roc curves were made as well as for CEA, and they are shown in Figures 3 and 4 with a 2-Y OS sensitivity and specificity respectively of 71.4 and 81.2%, and 1-Y DFS was respectively of 64.7 and 71.7%.
Survival analysis
5Y-OS and 5Y-DFS of our series were respectively of 60% and 75%. 5Y-OS of patients with a low preoperative CEA level was 70% vs. 45% of patients with high CEA level. The difference was statistically different with a p<0.05 ( Figure 5 ). Also, DSF showed ( Figure 6 ) a statistically significant difference with a percentage of 90% vs 65% in low and high groups respectively. Overall survival sub analysis showed also statistically significant differences (p<0.05) in T3-T4, N0, N+ patients according to CEA values (Figures 7a-7c) . No statistically significant difference was shown in T1-2 patients according to CEA value. Similar analyses were done according to preoperative CA 19.9 serum level. Figure 8 shows a 5Y-OS of 65% vs. 35% respectively in patients with normal or altered Ca19.9 with a statistically significant difference (p<0.05). Regarding this marker there were statistically significant differences again in T3-4 patients, but not in T1 and T2 ONES. On the contrary, there was a statistically significant difference in N0 patients, but not in N+ (Figures 9a and 9b) . Finally, we compared the overall survival of double positive patients (CEA+, CA 19-9+) with single positive, and we found a statistically significant difference (P<0.05). The double positive had a much worse prognosis than the single positive (Figure 10) . At the multivariate analysis, both the preoperative CEA and Ca19.9 resulted as independent prognostic factors for survival with a p<0.05.
Discussion
Tumor markers are substances that are produced by tumor cells and after secreted into the circulation in detectable amounts. Most of them are greatly limited for screening the asymptomatic population, being neither sensitive enough nor specific enough to detect early disease and small tumors [6] . CEA and Ca 19.9 are the most common and popular neoplastic markers investigated in colorectal patients and they are used routinely in the management of this disease. CEA is a high-molecular weight glycoprotein among the immunoglobulin superfamily of molecules that plays a pivotal role in cellular biological phenomena as adhesion, immunity or apoptosis of the tumor cells [7] .
Ca 19.9 exerts its function as an adhesion molecule playing an important role in the process of the progression and invasion of the tumor. In spite of previous investigations, the survival significance of these neoplastic markers remains controversial, and it remains unclear whether monitoring them brings any clinical benefit in the management of colorectal cancer patients [8] . Pre-operative CEA is incorporated into many useful prognostic scoring systems to stratify patients at high risk of recurrences, localized in the liver after curative surgery. On the other hand, Ca 19.9 shows lesser prognostic value, if evaluated alone; for this reason, itis not so frequently used in the management of colorectal cancer patients. It could be useful to evaluate it in combination with CEA for monitoring recurrences. However, the American Society of Clinical Oncology suggests that there are too few clinical studies and evidence for using Ca 19.9 in monitoring colorectal patients. In our study we would like to investigate the prognostic value of survival and disease-free survival of pre-operative serum CEA and Ca19.9 correlating them to clinical and pathological patients' features. Actually, it is well accepted that they are not specific for the detection of colon cancer and they cannot be monitored for the detection of an adenocarcinoma in situ. On the other hand, CEA is often elevated in advanced colon disease mainly in the metastatic one. This fact is well illustrated in the work of Levy et al. [9] , in which he stated that CEA and Ca 19-9 are statistically and significantly different in early and metastatic colorectal cancer, where CEA plays a role in the metastatic process. The role of CEA in cancer dissemination was revealed in a study by Hostetter et al. [10] , who showed that the rate of liver metastasis in mice transplanted with colorectal tumours strongly increased after CEA injection in the murine model. Several studies showed that more CEA per gram of total protein was produced by well-differentiated colorectal cancers than by poorly differentiated specimens [11] [12] [13] . Serum CEA has also been reported to trend higher in patients with welldifferentiated tumors than in those with poorly differentiated tumors [14] . Not all the advanced colon cancers show an elevation of CEA due to the biological tumoral characteristics. This fact was confirmed by the review written by Duffy [15] who suggested that a lack of differentiation or poor differentiation might explain why some patients, with advanced colorectal cancer, didn't show increased serum concentrations of CEA. On the other hand, our results suggested that CEA elevation is not statistically correlated to tumor differentiation or histological type (p>0.05). Nakatani [16] and his colleagues demonstrated that the cancer located at the sigma showed higher concentrations of CEA and Ca 19.9 compared to the other cancer side. In our series both CEA and Ca 19.9 are not correlated in a statistically significant way to cancer side (p>0.05). Basing on 1y-DFS-ROC curve, pre-operative elevated CEA shows a strong importance to predict recurrences at one year after curative surgery (CEA specificity: 93%). Thus, it allows to stratify patients before the surgical procedure, discriminating patients at high risk of recurrences who could benefit of a chemotherapy strategy or a stricter follow-up after radical surgery. Previous reports showed a significant association between elevated serum Ca 19-9 and poor prognosis related to disease stage in the preoperative setting. The association of Ca 19-9 with prognosis was found to be better than the CEA [17] . In contrast, other publications have reported that the use of Ca 19-9 was very limited. The antigen was found to have no value in the screening of colon cancer patients because its positive predictive value was less than 1%. [18] . In our study, Ca 19-9 did not show a big sensitivity and specificity both for OS and DFS.
In our studied patients, a pre-operative elevation of serum Ca 19.9 could be important for N0 patients who regularly are not addressed to chemotherapy. An elevation of Ca 19.9 could represent a signal to guide in these patients a more aggressive medical therapy or a more aggressive post-surgical follow-up. Our study has some limitations because, first, it includes a small number of patients; secondly it is a retrospective work, and thirdly a long-term follow up is required to provide more prognostic information.
Conclusion
Given that colorectal cancer is a common cause of death worldwide, an effort either to achieve early diagnosis or to identify patients with poor prognosis in the preoperative period is needed to support patient management after surgical treatment. Tumoral markers are known not to be suitable in population screening for their limitations, and our results confirmed the low sensitivity of both CEA and Ca 19.9. In the present study, we found that preoperative serum CEA might advice an appropriate post-surgical follow-up when the patient is at high risk of recurrences. Whereas pre-operative Ca19.9 might indicate a very poor prognosis in N0 patients, suggesting a potential benefit of chemotherapy in these patients. We therefore recommend routine preoperative tests to evaluate both serum CEA and Ca19.9 in colorectal cancer.
Further studies into the molecular basis of tumor biology might contribute the current understanding of the nature of these tumor markers.
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